Clinical Trial Update: Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel plus atezolizumab given before surgery in triple-negative breast cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Tecentriq (atezolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Breast Adenocarcinoma, Invasive Breast Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-02-17